title: Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies.
abstract: Subcutaneous administration of immunoglobulin (IGSC) in a home setting, compared with intravenous administration, can improve patient quality of life. During IGSC, however, the subcutaneous extracellular matrix inhibits flow and fluid entry into the vascular compartment, which limits the amount of drug delivered. Recombinant human hyaluronidase (rHuPH20) increases the absorption and dispersion of infused fluids and drugs. Results from a Phase III, prospective, open-label, noncontrolled study of patients with primary immunodeficiencies indicated that IGSC infusion, facilitated by rHuPH20, is well tolerated and delivers infusion volumes at treatment intervals and rates equivalent to intravenous administration. This drug evaluation provides an overview of rHuPH20 and results of clinical studies of IGSC infusion facilitated by rHuPH20 in patients with primary immunodeficiencies.
authors.affiliation: DallasAllergyImmunology, 7777 Forest Lane, Suite B-332, Dallas, TX, 75230, USA.
authors.forename: Richard L
authors.initials: RL
authors.lastname: Wasserman
mesh_terms: D017326:Clinical Trials, Phase III as Topic; D017074:Common Variable Immunodeficiency / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use*; D007074:Immunoglobulin G / Q000627:therapeutic use*; D055104:Infusions, Subcutaneous; D011994:Recombinant Proteins
chemical_list: D007074:Immunoglobulin G; D011994:Recombinant Proteins; D006821:Hyaluronoglucosaminidase
keywords: IgG; Phase III; facilitated subcutaneous infusion; hyaluronidase; pharmacokinetics; primary immunodeficiency disease; recombinant human hyaluronidase; safety; tolerability